Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class ...
Pfizer seals the deal with Metsera for $10 billion after Novo Nordisk bowed out; President Donald Trump welcomes executives ...
The strategic initiative will extend Metagenomi’s cash runway into the fourth quarter of 2027. That same year, the company ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year ...
Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback